文献速递造血干细胞移植与细胞治疗白血病

CD34+细胞剂量对清淋性单倍体异基因造血干细胞移植治疗急性髓系白血病临床结局的影响:欧洲血液与骨髓移植学会急性白血病工作组研究

CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT).
PubMed 文献 · Am J Hematol · 2020-05-01

该回顾性分析纳入414例首次或第二次完全缓解的成人急性髓系白血病患者,2006至2018年接受清淋性单倍体异基因外周血造血干细胞移植。中位随访23.3个月,2年总生存率64.5%。CD34+阈值4.96×10^6/kg以上组非复发死亡率更低、无白血病生存和总生存更长。

要点

  • 414例急性髓系白血病患者接受清淋性单倍体移植,中位CD34+剂量6.58×10^6/kg。
  • 2年总生存率64.5%,无白血病生存率57.3%,非复发死亡率23.3%。
  • CD34+>4.96×10^6/kg组非复发死亡率更低(HR 0.48),无白血病生存和总生存更长。

核心结论

  • CD34+细胞剂量>4.96×10^6/kg与更低的非复发死亡率和更长的无白血病生存及总生存相关,但需更大规模队列研究证实。

研究设计与样本

  • 回顾性分析纳入414例成人急性髓系白血病患者(中位年龄54岁,范围18-74岁),处于首次或第二次完全缓解,2006至2018年接受清淋性单倍体异基因外周血造血干细胞移植。
  • 移植物抗宿主病预防:293例使用移植后环磷酰胺,121例使用抗淋巴细胞血清;清髓性预处理179例,减低强度预处理235例。

主要发现

  • 中位随访23.3个月(范围12.1-41.8个月),2年总生存率64.5%(95%CI 59.3%-69.7%),无白血病生存率57.3%(95%CI 51.8%-62.7%),非复发死亡率23.3%(95%CI 19%-27.7%)。
  • III-IV级急性移植物抗宿主病第+100天发生率为14.6%,广泛性慢性移植物抗宿主病2年发生率为14.4%。
  • 13例(3.2%)患者发生移植物失败。
  • CD34+阈值定为4.96×10^6/kg,高剂量组(n=334)与低剂量组(n=80);高剂量组较低剂量组非复发死亡率更低(HR 0.48;95%CI 0.30-0.76),无白血病生存更长(HR 0.63;95%CI 0.43-0.91),总生存更长(HR 0.60;95%CI 0.40-0.88)。

关键数值与推荐

  • CD34+细胞剂量高剂量定义为>4.96×10^6/kg(n=334),低剂量定义为≤4.96×10^6/kg(n=80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需更大规模队列研究证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous observations have reported controversial conclusions regarding cell dose and survival endpoints after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a retrospective analysis on 414 adult patients (median age 54 years, range, 18-74 years) with acute myeloid leukemia (AML) in first and second complete remission. They received a T-cell replete allogeneic HSCT from haploidentical donors, using peripheral blood stem cells, between 2006-2018. Median number of infused CD34+ was 6.58 × 106 /kg (range, 2.2-31.2 × 106 /kg). Graft-vs-host disease (GVHD) prophylaxis was post-transplant cyclophosphamide in 293 patients and anti-lymphocyte serum in 121 patients. Conditioning was myeloablative in 179 patients and reduced-intensity in 235 patients. After a median follow-up of 23.3 months (range, 12.1-41.8 months), 2-year overall survival (OS) was 64.5% (95% CI 59.3%-69.7%) with leukemia-free survival (LFS) of 57.3% (95% CI 51.8%-62.7%) and non-relapse mortality (NRM) of 23.3% (95% CI 19%-27.7%). Grades III-IV acute GVHD day+100 incidence was 14.6% while extensive chronic GVHD was 14.4% at 2-years. Thirteen (3.2%) patients experienced graft failure. We found the optimal CD34+/kg threshold defining high (n = 334) vs low cell dose (n = 80) at 4.96 × 106 . Recipients of >4.96 × 106 /kg CD34+ cells experienced less NRM (Hazard ratio [HR] 0.48; 95% CI 0.30-0.76) and prolonged LFS (HR 0.63; 95% CI 0.43-0.91) and OS (HR 0.60; 95% CI 0.40-0.88) compared to those in the lower cell dose cohort. Larger cohort studies are needed to confirm these findings.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Maffini E, Labopin M, Blaise D, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2020. PMID: 32303111. doi:10.1002/ajh.25826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。